(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Role reversal: Ukraine moves training home and exports the lessons abroad - 2Geomagnetic storm grounds launch of Mars space weather satellites
- 3Guinea-Bissau's coup called a 'sham' by West African political figures
- 4Investigating Design and Individual Style: Track down Your Remarkable Look
- 5What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- Monetary Versatility: Get ready for Life's Unforeseen Difficulties
- Sports Shoes of 2024: Upgrade Execution and Solace
- UK forecast to face weaker growth and higher inflation from Iran war
- German hauliers warn soaring energy prices may soon impact consumers
- Find Wonderful Stream Voyage Objections On the planet
- Dwayne ‘the Rock’ Johnson opens up about being the 'new guy' again — and why this moment feels like a new life
- 4 Sound blocking Earphones for Prevalent Sound and Solace
- 6 Travel Services for Colorful Get-aways: Pick Your Fantasy Escape
- How did humans evolve, and will we evolve more?
